{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["IDO", "immunoregulation", "kynurenine pathway", "liver diseases", "liver injury"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34869457", "DateRevised": {"Year": "2023", "Month": "09", "Day": "21"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "11", "Day": "18"}], "Language": ["eng"], "ELocationID": ["756435", "10.3389/fmed.2021.756435"], "Journal": {"ISSN": "2296-858X", "JournalIssue": {"Volume": "8", "PubDate": {"Year": "2021"}}, "Title": "Frontiers in medicine", "ISOAbbreviation": "Front Med (Lausanne)"}, "ArticleTitle": "Emerging Roles on Immunological Effect of Indoleamine 2,3-Dioxygenase in Liver Injuries.", "Pagination": {"StartPage": "756435", "MedlinePgn": "756435"}, "Abstract": {"AbstractText": ["Indoleamine 2,3-dioxygenase (IDO) is one of the initial rate-limiting enzymes of the kynurenine pathway (KP), which causes immune suppression and induction of T cell anergy. It is associated with the imbalance of immune homeostasis in numerous diseases including cancer, chronic viral infection, allergy, and autoimmune diseases. Recently, IDO has extended its role to liver field. In this review, we summarize the dysregulation and potentials of IDO in the emerging field of liver injuries, as well as current challenges for IDO targets. In particular, we discuss unexpected conclusions against previous work published. IDO is induced by pro-inflammatory cytokines in liver dysfunction and exerts an immunosuppressive effect, whereas the improvement of liver injury may require consideration of multiple factors besides IDO."], "CopyrightInformation": "Copyright \u00a9 2021 Xu, Ling, Su, Su, Xu and Jiang."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Sir Run Run Hospital, Nanjing Medical University, Nanjing, China."}], "LastName": "Xu", "ForeName": "Lingyan", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Institute of Chinese Medicine and State Key Laboratory of Research on Bioactivities and Clinical Applications of Medicinal Plants, The Chinese University of Hong Kong, Hong Kong, China."}], "LastName": "Ling", "ForeName": "Jiawei", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Sir Run Run Hospital, Nanjing Medical University, Nanjing, China."}], "LastName": "Su", "ForeName": "Chang", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Sir Run Run Hospital, Nanjing Medical University, Nanjing, China."}, {"Identifier": [], "Affiliation": "School of Pharmacy, Nanjing Medical University, Nanjing, China."}], "LastName": "Su", "ForeName": "Yu-Wen", "Initials": "YW"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Sir Run Run Hospital, Nanjing Medical University, Nanjing, China."}], "LastName": "Xu", "ForeName": "Yan", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "New Drug Screening Center, Jiangsu Center for Pharmacodynamics Research and Evaluation, China Pharmaceutical University, Nanjing, China."}], "LastName": "Jiang", "ForeName": "Zhenzhou", "Initials": "Z"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Med (Lausanne)", "NlmUniqueID": "101648047", "ISSNLinking": "2296-858X"}, "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "arszalek-Grabska M, Walczak K, Gawel K, Wicha-Komsta K, Turski WA. Kynurenine emerges from the shadows \u2013 current knowledge on its fate and function. Pharmacol Ther. (2021) 225:107845. 10.1016/j.pharmthera.2021.107845", "ArticleIdList": ["10.1016/j.pharmthera.2021.107845", "33831481"]}, {"Citation": "Knyih\u00e1r-Csillik E, Chadaide Z, Mih\u00e1ly A, Krisztin-P\u00e9va B, Fenyo R, V\u00e9csei L. Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra. Acta Neuropathol. (2006) 112:127\u201337. 10.1007/s00401-006-0086-4", "ArticleIdList": ["10.1007/s00401-006-0086-4", "16788821"]}, {"Citation": "Capece L, Arrar M, Roitberg AE, Yeh SR, Estrin DA. Substrate stereo-specificity in tryptophan dioxygenase and indoleamine 2,3- dioxygenase. Proteins. (2010) 78:2961\u201372. 10.1002/prot.22819", "ArticleIdList": ["10.1002/prot.22819", "PMC2939288", "20715188"]}, {"Citation": "Stefan L\u00f6b AK, Derek Zieker, Bj\u00f6rn LDMB, Hans-Georg R, Gerhard O, Peter T. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother. (2009) 58:153\u20137. 10.1007/s00262-008-0513-6", "ArticleIdList": ["10.1007/s00262-008-0513-6", "18418598"]}, {"Citation": "Merlo L, Duhadaway JB, Montgomery JD, Peng WD, Mandik-Nayak L. Differential roles of IDO1 and IDO2 in T and B Cell inflammatory immune responses. Front Immunol. (2020) 11:1861. 10.3389/fimmu.2020.01861", "ArticleIdList": ["10.3389/fimmu.2020.01861", "PMC7461966", "32973768"]}, {"Citation": "Helen JB, Angeles S-P, Silvia W, Christopher JDA, Florian A, Jenny M, et al. . Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene. (2007) 396:203\u201313. 10.1016/j.gene.2007.04.010", "ArticleIdList": ["10.1016/j.gene.2007.04.010", "17499941"]}, {"Citation": "Badawy AAB. Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. Int J Tryptophan Res. (2017) 10:117864691769193. 10.1177/1178646917691938", "ArticleIdList": ["10.1177/1178646917691938", "PMC5398323", "28469468"]}, {"Citation": "Platten M, Nollen EAA, R\u00f6hrig UF, Fallarino F, Opitz CA. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. (2019) 18:379\u2013401. 10.1038/s41573-019-0016-5", "ArticleIdList": ["10.1038/s41573-019-0016-5", "30760888"]}, {"Citation": "Pallotta MT, Rossini S, Suvieri C, Coletti A, Orabona C, Macchiarulo A, et al. . Indoleamine 2,3-dioxygenase 1 (IDO1): an up-to-date overview of an eclectic immunoregulatory enzyme. FEBS J. (2021). 10.1111/febs.16086", "ArticleIdList": ["10.1111/febs.16086", "PMC9786828", "34145969"]}, {"Citation": "Badawy AB. Tryptophan availability for kynurenine pathway metabolism across the life span: control mechanisms and focus on aging, exercise, diet and nutritional supplements. Neuropharmacology. (2017) 112:248\u201363. 10.1016/j.neuropharm.2015.11.015", "ArticleIdList": ["10.1016/j.neuropharm.2015.11.015", "26617070"]}, {"Citation": "Jones SP, Franco NF, Bianca V, Gayathri S, Brown DA, Josien DB, et al. . Expression of the kynurenine pathway in human peripheral blood mononuclear cells: implications for inflammatory and neurodegenerative disease. PLoS ONE. (2015) 10:e0131389. 10.1371/journal.pone.0131389", "ArticleIdList": ["10.1371/journal.pone.0131389", "PMC4482723", "26114426"]}, {"Citation": "Zou MH. Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation. Front Biosci. (2015) 20:1116\u201343. 10.2741/4363", "ArticleIdList": ["10.2741/4363", "PMC4911177", "25961549"]}, {"Citation": "Sorgdrager FJH, Naud\u00e9 PJW, Kema IP, Nollen EA, Deyn PPD. Tryptophan metabolism in inflammaging: from biomarker to therapeutic target. Front Immunol. (2019) 10:2565. 10.3389/fimmu.2019.02565", "ArticleIdList": ["10.3389/fimmu.2019.02565", "PMC6833926", "31736978"]}, {"Citation": "Prendergast GC, Malachowski WJ, Mondal A, Scherle P, Muller AJ. Indoleamine 2,3-Dioxygenase and its therapeutic inhibition in cancer. Int Rev Cell Mol Biol. (2017) 336:175\u2013203. 10.1016/bs.ircmb.2017.07.004", "ArticleIdList": ["10.1016/bs.ircmb.2017.07.004", "PMC6054468", "29413890"]}, {"Citation": "Iwamoto N, Ito H, Ando K, Ishikawa T, Hara A, Taguchi A, et al. . Upregulation of indoleamine 2,3-dioxygenase in hepatocyte during acute hepatitis caused by hepatitis B virus-specific cytotoxic T lymphocytes in vivo. Liver Int. (2009) 29:277\u201383. 10.1111/j.1478-3231.2008.01748.x", "ArticleIdList": ["10.1111/j.1478-3231.2008.01748.x", "18397228"]}, {"Citation": "Larrea E, Riezu-Boj JI, Gil-Guerrero L, Casares N, Aldabe R, Sarobe P, et al. . Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol. (2007) 81:3662\u20136. 10.1128/JVI.02248-06", "ArticleIdList": ["10.1128/JVI.02248-06", "PMC1866047", "17229698"]}, {"Citation": "Yoshio S, Kanto T. Host\u2013virus interactions in hepatitis B and hepatitis C infection. J Gastroenterol. (2016) 51:409\u201320. 10.1007/s00535-016-1183-3", "ArticleIdList": ["10.1007/s00535-016-1183-3", "26894594"]}, {"Citation": "Luan X, Liao W, Lai X, He Y, Liu Y, Gong J, et al. . Dynamic changes of indoleamine 2,3-dioxygenase of kupffer cells in rat liver transplant rejection and tolerance. Transplant Proc. (2012) 44:1045\u20137. 10.1016/j.transproceed.2012.01.033", "ArticleIdList": ["10.1016/j.transproceed.2012.01.033", "22564621"]}, {"Citation": "Gerald Brandacher, Raimund Margreiter, Fuchs D. Implications of IFN-gamma-mediated tryptophan catabolism on solid organ transplantation. Curr Drug Metab. (2007) 8:273\u201382. 10.2174/138920007780362536", "ArticleIdList": ["10.2174/138920007780362536", "17430115"]}, {"Citation": "Lytton SD, Osiecki M, Cukrowska B, Wierzbicka A, Goliszek M, Socha P, et al. . Tryptophan-kynurenine profile in pediatric autoimmune hepatitis. Immunol Res. (2019) 67:39\u201347. 10.1007/s12026-019-9068-1", "ArticleIdList": ["10.1007/s12026-019-9068-1", "30666511"]}, {"Citation": "Asghar K, Farooq A, Zulfiqar B, Rashid MU. Indoleamine 2,3-dioxygenase: as a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma. World J Gastroenterol. (2017) 23:2286. 10.3748/wjg.v23.i13.2286", "ArticleIdList": ["10.3748/wjg.v23.i13.2286", "PMC5385395", "28428708"]}, {"Citation": "De Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. (2006) 6:24\u201337. 10.1038/nrc1782", "ArticleIdList": ["10.1038/nrc1782", "16397525"]}, {"Citation": "Xiao Y, Christou H, Liu L, Visner G, Mitsialis SA, Kourembanas S, et al. . Endothelial indoleamine 2,3-dioxygenase protects against development of pulmonary hypertension. Am J Respir Crit Care Med. (2013) 188:482\u201391. 10.1164/rccm.201304-0700OC", "ArticleIdList": ["10.1164/rccm.201304-0700OC", "PMC3778740", "23822766"]}, {"Citation": "Sakash JB, Byrne GI, Lichtman A, Libby P. Cytokines induce indoleamine 2,3-dioxygenase expression in human atheroma-associated cells: implications for persistent chlamydophila pneumoniae infection. Infect Immun. (2002) 70:3959\u201361. 10.1128/IAI.70.7.3959-3961.2002", "ArticleIdList": ["10.1128/IAI.70.7.3959-3961.2002", "PMC128116", "12065543"]}, {"Citation": "Koyo H, Tatsuya K, Shoko K, Sachiyo Y, Tokuhiro M, Naruyasu K, et al. . Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection. J Gastroenterol. (2013) 48:660\u201370. 10.1007/s00535-012-0667-z", "ArticleIdList": ["10.1007/s00535-012-0667-z", "22976933"]}, {"Citation": "Mailankot M, Nagaraj RH. Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human lens epithelial cells: apoptosis through the formation of 3-hydroxykynurenine. Int J Biochem Cell Biol. (2010) 42:1446\u201354. 10.1016/j.biocel.2010.04.014", "ArticleIdList": ["10.1016/j.biocel.2010.04.014", "PMC2910246", "20435158"]}, {"Citation": "Alberati-Giani D, Ricciardi-Castagnoli P, Khler C, Cesura AM. Regulation of the kynurenine pathway by IFN-\u03b3 in murine cloned macrophages and microglial cells. J Neurochem. (2002) 66:996\u20131004. 10.1046/j.1471-4159.1996.66030996.x", "ArticleIdList": ["10.1046/j.1471-4159.1996.66030996.x", "8769859"]}, {"Citation": "Mellor A. IDO expression by dendritic cells : tolerance and tryptophan catabolism. Nat Rev Immunol. (2004) 4:762\u201374. 10.1038/nri1457", "ArticleIdList": ["10.1038/nri1457", "15459668"]}, {"Citation": "Guillonneau C, Hill M, Hubert FX, Chiffoleau E, Anegon I. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest. (2007) 117:1096\u2013106. 10.1172/JCI28801", "ArticleIdList": ["10.1172/JCI28801", "PMC1839240", "17404623"]}, {"Citation": "Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol. (2000) 164:3596\u20139. 10.4049/jimmunol.164.7.3596", "ArticleIdList": ["10.4049/jimmunol.164.7.3596", "10725715"]}, {"Citation": "Reena Rani MBJ, Senad D, De'Broski RH. IFN-\u03b3-Driven IDO production from macrophages protects IL-4R\u03b1-deficient mice against lethality during schistosoma mansoni infection. Am J Pathol. (2012) 180:2001\u20138. 10.1016/j.ajpath.2012.01.013", "ArticleIdList": ["10.1016/j.ajpath.2012.01.013", "PMC3349826", "22426339"]}, {"Citation": "Kubes P, Jenne C. Immune responses in the liver. Annu Rev Immunol. (2018) 36:247\u201377. 10.1146/annurev-immunol-051116-052415", "ArticleIdList": ["10.1146/annurev-immunol-051116-052415", "29328785"]}, {"Citation": "Munn D, Zhou M, Attwood J, Bondarev I, Conway S, Marshall B, et al. . Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. (1998) 281:1191\u20133. 10.1126/science.281.5380.1191", "ArticleIdList": ["10.1126/science.281.5380.1191", "9712583"]}, {"Citation": "Barth H, Raghuraman S. Persistent infectious diseases say \u2013 IDO. Role of indoleamine-2,3-dioxygenase in disease pathogenesis and implications for therapy. Crit Rev Microbiol. (2012) 40:360. 10.3109/1040841X.2012.742037", "ArticleIdList": ["10.3109/1040841X.2012.742037", "23174025"]}, {"Citation": "Mangge H, Stelzer I, Reininghaus EZ, Weghuber D, Postolache TT, Fuchs D. Disturbed tryptophan metabolism in cardiovascular disease. Curr Med Chem. (2014) 21:1931\u20137. 10.2174/0929867321666140304105526", "ArticleIdList": ["10.2174/0929867321666140304105526", "PMC4922792", "24606499"]}, {"Citation": "Filippini P, Del Papa N, Sambataro D, Del Bufalo A, Locatelli F, Rutella S. Emerging concepts on inhibitors of indoleamine 2,3-dioxygenase in rheumatic diseases. Curr Med Chem. (2012) 19:5381\u201393. 10.2174/092986712803833353", "ArticleIdList": ["10.2174/092986712803833353", "22963664"]}, {"Citation": "Modoux M, Rolhion N, Mani S, Sokol H. Tryptophan metabolism as a pharmacological target. Trends Pharmacol Sci. (2021) 42:60\u201373. 10.1016/j.tips.2020.11.006", "ArticleIdList": ["10.1016/j.tips.2020.11.006", "33256987"]}, {"Citation": "Le Naour J, Galluzzi L, Zitvogel L, Kroemer G, Vacchelli E. Trial watch: IDO inhibitors in cancer therapy. OncoImmunology. (2020) 9:1777625. 10.1080/2162402X.2020.1777625", "ArticleIdList": ["10.1080/2162402X.2020.1777625", "PMC7466863", "32934882"]}, {"Citation": "Liu XH, Zhai XY. Role of tryptophan metabolism in cancers and therapeutic implications. Biochimie. (2021) 182:131\u20139. 10.1016/j.biochi.2021.01.005", "ArticleIdList": ["10.1016/j.biochi.2021.01.005", "33460767"]}, {"Citation": "Wang Q, Zhang M, Ding Y, Wang Q, Zhang W, Song P, et al. . Activation of NAD(P)H oxidase by tryptophan-derived 3-hydroxykynurenine accelerates endothelial apoptosis and dysfunction in vivo. Circ Res. (2014) 114:480\u201392. 10.1161/CIRCRESAHA.114.302113", "ArticleIdList": ["10.1161/CIRCRESAHA.114.302113", "PMC4104160", "24281189"]}, {"Citation": "Bogdan C. Macrophages as host, effector and immunoregulatory cells in leishmaniasis: impact of tissue micro-environment and metabolism. Cytokine X. (2020) 2:100041. 10.1016/j.cytox.2020.100041", "ArticleIdList": ["10.1016/j.cytox.2020.100041", "PMC7885870", "33604563"]}, {"Citation": "Yun TJ, Lee JS, Machmach K, Shim D, Choi J, Wi YJ, et al. . Indoleamine 2,3-dioxygenase-expressing aortic plasmacytoid dendritic cells protect against atherosclerosis by induction of regulatory T cells. Cell Metab. (2016) 23:852\u201366. 10.1016/j.cmet.2016.04.010", "ArticleIdList": ["10.1016/j.cmet.2016.04.010", "27166946"]}, {"Citation": "Munn DH, Sharma M, Baban B, Harding HP, Zhang Y, Ron D, et al. . GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. (2005) 22:633\u201342. 10.1016/j.immuni.2005.03.013", "ArticleIdList": ["10.1016/j.immuni.2005.03.013", "15894280"]}, {"Citation": "Sonner JK, Deumelandt K, Ott M, Thom\u00e9 C, Platten M. The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas. Oncoimmunology. (2016) 5:e1240858. 10.1080/2162402X.2016.1240858", "ArticleIdList": ["10.1080/2162402X.2016.1240858", "PMC5214097", "28123877"]}, {"Citation": "Badawy AB, Namboodiri A, Moffett JR. The end of the road for the tryptophan depletion concept in pregnancy and infection. Clin Sci. (2016) 130:1327\u201333. 10.1042/CS20160153", "ArticleIdList": ["10.1042/CS20160153", "PMC4926258", "27358028"]}, {"Citation": "Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. (1999) 189:1363\u201372. 10.1084/jem.189.9.1363", "ArticleIdList": ["10.1084/jem.189.9.1363", "PMC2193062", "10224276"]}, {"Citation": "Pallotta MT, Orabona C, Volpi C, Vacca C, Grohmann U. Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol. (2011) 12:870\u20138. 10.1038/ni.2077", "ArticleIdList": ["10.1038/ni.2077", "21804557"]}, {"Citation": "van Baren N, Van den Eynde BtJ. Tryptophan-degrading enzymes in tumoral immune resistance. Front Immunol. (2015) 6:34. 10.3389/fimmu.2015.00034", "ArticleIdList": ["10.3389/fimmu.2015.00034", "PMC4315104", "25691885"]}, {"Citation": "Knox WE. Two mechanisms which increase in vivo the liver tryptophan peroxidase activity: specific enzyme adaptation and stimulation of the pituitary-adrenal system. Br J Exp Pathol. (1951) 32:462\u20139.", "ArticleIdList": ["PMC2073205", "14886511"]}, {"Citation": "Chen LB, Zhu SP, Liu TP, Zhao H, Hu R. Cancer associated fibroblasts promote renal cancer progression through a TDO/Kyn/AhR dependent signaling pathway. Front Oncol. (2021) 11:628821. 10.3389/fonc.2021.628821", "ArticleIdList": ["10.3389/fonc.2021.628821", "PMC8027476", "33842334"]}, {"Citation": "Ito H, Hoshi M, Ohtaki H, Taguchi A, Ando K, Ishikawa T, et al. . Ability of IDO to attenuate liver injury in \u03b1-galactosylceramide\u2013induced hepatitis model. J Immunol. (2010) 185:4554\u201360. 10.4049/jimmunol.0904173", "ArticleIdList": ["10.4049/jimmunol.0904173", "20844202"]}, {"Citation": "Chatamra K, Proctor E. Phenobarbitone-induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis. Br J Exp Pathol. (1981) 62:283\u20138.", "ArticleIdList": ["PMC2041698", "7248170"]}, {"Citation": "Tomasi A, Albano E, Banni S, Botti B, Corongiu F, Dessi MA, et al. . Free-radical metabolism of carbon tetrachloride in rat liver mitochondria. A study of the mechanism of activation. Biochem J. (1987) 246:313\u20137. 10.1042/bj2460313", "ArticleIdList": ["10.1042/bj2460313", "PMC1148278", "2825631"]}, {"Citation": "Ogiso H, Ito H, Ando T, Arioka Y, Kanbe A, Ando K, et al. . The deficiency of indoleamine 2,3-dioxygenase aggravates the CCl4-induced liver fibrosis in mice. PLoS ONE. (2016) 11:e0162183. 10.1371/journal.pone.0162183", "ArticleIdList": ["10.1371/journal.pone.0162183", "PMC5012673", "27598994"]}, {"Citation": "Li D, Cai H, Hou M, Fu D, Ma Y, Luo Q, et al. . Effects of indoleamine 2,3-dioxygenases in carbon tetrachloride-induced hepatitis model of rats. Cell Biochem Funct. (2012) 30:309\u201314. 10.1002/cbf.2803", "ArticleIdList": ["10.1002/cbf.2803", "22249930"]}, {"Citation": "Weichao Zhong LG, Zhenting Z, Haiyan L, Chun C, Peng H, Weiliang H, et al. . Indoleamine 2,3-dioxygenase 1 deficiency attenuates CCl4-induced fibrosis through Th17 cells down-regulation and tryptophan 2,3-dioxygenase compensation. Oncotarget. (2017) 8:40486\u2013500. 10.18632/oncotarget.17119", "ArticleIdList": ["10.18632/oncotarget.17119", "PMC5522192", "28465467"]}, {"Citation": "Hoshi M, Osawa Y, Nakamoto K, Morita N, Yamamoto Y, Ando T, et al. . Kynurenine produced by indoleamine 2,3-dioxygenase 2 exacerbates acute liver injury by carbon tetrachloride in mice. Toxicology. (2020) 438:152458. 10.1016/j.tox.2020.152458", "ArticleIdList": ["10.1016/j.tox.2020.152458", "32289347"]}, {"Citation": "Kanai M, Funakoshi H, Takahashi H, Hayakawa T, Mizuno S, Matsumoto K, et al. . Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol Brain. (2009) 2:8. 10.1186/1756-6606-2-8", "ArticleIdList": ["10.1186/1756-6606-2-8", "PMC2673217", "19323847"]}, {"Citation": "Yuasa HJ, Ball HJ, Ho YF, Austin CJD, Whittington CM, Belov K, et al. . Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases. Comp Biochem Physiol B Biochem Mol Biol. (2009) 153:137\u201344. 10.1016/j.cbpb.2009.02.002", "ArticleIdList": ["10.1016/j.cbpb.2009.02.002", "19402226"]}, {"Citation": "Snyder IS, Agarwal MK, Berry LJ. Influence of carbon tetrachloride on inducible liver enzymes and response to endotoxin in mice. J Bacteriol. (1967) 94:1817. 10.1128/jb.94.6.1817-1823.1967", "ArticleIdList": ["10.1128/jb.94.6.1817-1823.1967", "PMC276910", "4383750"]}, {"Citation": "Nagano J, Shimizu M, Hara T, Shirakami Y, Kochi T, Nakamura N, et al. . Effects of indoleamine 2,3-dioxygenase deficiency on high-fat diet-induced hepatic inflammation. PLoS ONE. (2013) 8:e73404. 10.1371/journal.pone.0073404", "ArticleIdList": ["10.1371/journal.pone.0073404", "PMC3767792", "24039933"]}, {"Citation": "Badawy A, Morgan CJ, Davis NR, Dacey A. High-fat diets increase tryptophan availability to the brain: importance of choice of the control diet. Biochem J. (1984) 217:863. 10.1042/bj2170863", "ArticleIdList": ["10.1042/bj2170863", "PMC1153294", "6712603"]}, {"Citation": "Badawy AAB, Guillemin G. The Plasma [Kynurenine]/[Tryptophan] Ratio and Indoleamine 2,3-Dioxygenase: Time for Appraisal. Int J Tryptophan Res. (2019) 12:117864691986897. 10.1177/1178646919868978", "ArticleIdList": ["10.1177/1178646919868978", "PMC6710706", "31488951"]}, {"Citation": "Ogawa K HT, Shimizu M, Ninomiya S, J N. Suppression of azoxymethane-induced colonic preneoplastic lesions in rats by 1-methyltryptophan, an inhibitor of indoleamine 2,3dioxygenase. Cancer Sci. (2012) 103:951\u20138. 10.1111/j.1349-7006.2012.02237.x", "ArticleIdList": ["10.1111/j.1349-7006.2012.02237.x", "PMC7659269", "22320717"]}, {"Citation": "Zeng T, Deng G, Zhong W, Gao Z, Ma S, Mo C, et al. . Indoleamine 2, 3-dioxygenase 1enhanceshepatocytes ferroptosis in acute immune hepatitis associated with excess nitrative stress - ScienceDirect. Free Radic Biol Med. (2020) 152:668\u201379. 10.1016/j.freeradbiomed.2020.01.009", "ArticleIdList": ["10.1016/j.freeradbiomed.2020.01.009", "31945497"]}, {"Citation": "Tiegs G, Hentschel J, Wendel AA. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest. (1992) 90:196\u2013203. 10.1172/JCI115836", "ArticleIdList": ["10.1172/JCI115836", "PMC443081", "1634608"]}, {"Citation": "Heymann F, Hamesch K, Weiskirchen R, Tacke F. The concanavalin a model of acute hepatitis in mice. Lab Anim. (2015) 49(Suppl. 1):12\u201320. 10.1177/0023677215572841", "ArticleIdList": ["10.1177/0023677215572841", "25835734"]}, {"Citation": "Mo C, Xie S, Liu B, Zhong W, Zeng T, Huang S, et al. . Indoleamine 2,3-dioxygenase 1 limits hepatic inflammatory cells recruitment and promotes bile duct ligation-induced liver fibrosis. Cell Death Dis. (2021) 12:16. 10.1038/s41419-020-03277-0", "ArticleIdList": ["10.1038/s41419-020-03277-0", "PMC7791029", "33414436"]}, {"Citation": "Zhou Q, Shi Y, Chen C, Wu F, Chen Z. A narrative review of the roles of indoleamine 2,3-dioxygenase and tryptophan-2,3-dioxygenase in liver diseases. Ann Transl Med. (2021) 9:174. 10.21037/atm-20-3594", "ArticleIdList": ["10.21037/atm-20-3594", "PMC7867903", "33569476"]}, {"Citation": "Avila MA, Shibata Y, Hara T, Nagano J, Nakamura N, Ohno T, et al. . The role of indoleamine 2,3-dioxygenase in diethylnitrosamine-induced liver carcinogenesis. PLoS ONE. (2016) 11:e0146279. 10.1371/journal.pone.0146279", "ArticleIdList": ["10.1371/journal.pone.0146279", "PMC4699706", "26727596"]}, {"Citation": "Yu-Chun L, Chao-Long C, Toshiaki N, Shigeru G, Ying-Hsien K, Li-Wen H, et al. . Immunological role of indoleamine 2,3-dioxygenase in rat liver allograft rejection and tolerance. J Gastroenterol Hepatol. (2010) 23:e243\u201350. 10.1111/j.1440-1746.2007.05036.x", "ArticleIdList": ["10.1111/j.1440-1746.2007.05036.x", "17645734"]}, {"Citation": "Hirofumi O, Hiroyasu I, Kazuki A, Tetsuya I, Masato H, Tatsuya A, et al. . Kynurenine production mediated by indoleamine 2,3-dioxygenase aggravates liver injury in HBV-specific CTL-induced fulminant hepatitis. Biochim Biophys Acta. (2014) 1842:1464\u201371. 10.1016/j.bbadis.2014.04.015", "ArticleIdList": ["10.1016/j.bbadis.2014.04.015", "24768802"]}, {"Citation": "Yao W, Gu H, Zhu J, Barding G, Cheng H, Bao B, et al. . Integrated plasma and urine metabolomics coupled with HPLC/QTOF-MS and chemometric analysis on potential biomarkers in liver injury and hepatoprotective effects of Er-Zhi-Wan. Anal Bioanal Chem. (2014) 406:7367\u201378. 10.1007/s00216-014-8169-x", "ArticleIdList": ["10.1007/s00216-014-8169-x", "25245419"]}, {"Citation": "Chang H, Meng HY, Liu SM, Wang Y, Yang XX, Lu F, et al. . Identification of key metabolic changes during liver fibrosis progression in rats using a urine and serum metabolomics approach. Sci Rep. (2017) 7:11433. 10.1038/s41598-017-11759-z", "ArticleIdList": ["10.1038/s41598-017-11759-z", "PMC5595818", "28900168"]}, {"Citation": "Han Y, Yunzhou L, Zongying X, Dingnan W, Shaohua S, Huifang D, et al. . Identification of potential biomarkers in cholestasis and the therapeutic effect of melatonin by metabolomics, multivariate data and pathway analyses. Int J Mol Med. (2018) 42:2515\u201326. 10.3892/ijmm.2018.3859", "ArticleIdList": ["10.3892/ijmm.2018.3859", "PMC6192756", "30226547"]}, {"Citation": "Lin H, Teng H, Wu W, Li Y, Lv G, Huang X, et al. . Pharmacokinetic and metabolomic analyses of mangiferin calcium salt in rat models of type 2 diabetes and non-alcoholic fatty liver disease. BMC Pharmacol Toxicol. (2020) 21:59. 10.1186/s40360-020-00438-x", "ArticleIdList": ["10.1186/s40360-020-00438-x", "PMC7409647", "32762728"]}, {"Citation": "Cho T, Kok LY, Uetrecht J. Testing possible risk factors for idiosyncratic drug-induced liver injury using an amodiaquine mouse model and co-treatment with 1-methyl-d-tryptophan or acetaminophen. ACS Omega. (2021) 6:4656\u201362. 10.1021/acsomega.0c05352", "ArticleIdList": ["10.1021/acsomega.0c05352", "PMC7905801", "33644572"]}, {"Citation": "Too LK, Li KM, Suarna C, Maghzal GJ, Stocker R, Mcgregor IS. Deletion of TDO2, IDO-1 and IDO-2 differentially affects mouse behavior and cognitive function. Behav Brain Res. (2016) 312:102\u201317. 10.1016/j.bbr.2016.06.018", "ArticleIdList": ["10.1016/j.bbr.2016.06.018", "27316339"]}, {"Citation": "Cl\u00e0ria J, Moreau R, Fenaille F, Amor\u00f3s A, Junot C, Gronbaek H, et al. . Orchestration of tryptophan-kynurenine pathway, acute decompensation, and acute-on-chronic liver failure in cirrhosis. Hepatology. (2019) 69:1686\u2013701. 10.1002/hep.30363", "ArticleIdList": ["10.1002/hep.30363", "30521097"]}, {"Citation": "Badawy A. Letter to the editor: the kynurenine pathway in hepatic cirrhosis. Hepatology. (2019) 70:1077\u20138. 10.1002/hep.30680", "ArticleIdList": ["10.1002/hep.30680", "31032981"]}, {"Citation": "Hijikata Y, Hara K, Shiozaki Y, Murata K, Sameshima Y. Determination of free tryptophan in plasma and its clinical applications. J Clin Chem Clin Biochem. (1984) 22:291\u2013300. 10.1515/cclm.1984.22.4.291", "ArticleIdList": ["10.1515/cclm.1984.22.4.291", "6330273"]}, {"Citation": "Cao G, Zhu R, Jiang T, Tang D, Su T. Danshensu, a novel indoleamine 2,3-dioxygenase1 inhibitor, exerts anti-hepatic fibrosis effects via inhibition of JAK2-STAT3 signaling. Phytomedicine. (2019) 63:153055. 10.1016/j.phymed.2019.153055", "ArticleIdList": ["10.1016/j.phymed.2019.153055", "31377585"]}, {"Citation": "Mo C, Xie S, Zeng T, Lai Y, Lv Z. Ginsenoside-Rg1 acts as an IDO1 inhibitor, protects against liver fibrosis via alleviating IDO1-mediated the inhibition of DCs maturation. Phytomedicine. (2021) 84:153524. 10.1016/j.phymed.2021.153524", "ArticleIdList": ["10.1016/j.phymed.2021.153524", "33667840"]}, {"Citation": "Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. (2012) 380:2095\u2013128. 10.1016/S0140-6736(12)61728-0", "ArticleIdList": ["10.1016/S0140-6736(12)61728-0", "23245604"]}, {"Citation": "Koziel MJ. Cellular immune responses against hepatitis C virus. Clin Infect Dis. (2005) 41(Suppl. 1):S25\u201331. 10.1086/429492", "ArticleIdList": ["10.1086/429492", "16265610"]}, {"Citation": "Xiao-Song H RB, Lopez-Labrador FX. Quantitative analysis of hepatitis C virus-specific CDS8+ T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci USA. (1999) 96:5692\u20137. 10.1073/pnas.96.10.5692", "ArticleIdList": ["10.1073/pnas.96.10.5692", "PMC21922", "10318946"]}, {"Citation": "Schirren CA, Jung MC, Gerlach JT, Worzfeld T, Baretton G, Mamin M, et al. . Liver-derived hepatitis C virus (HCV)-specific CD4(+) T cells recognize multiple HCV epitopes and produce interferon gamma. Hepatology. (2000) 32:597\u2013603. 10.1053/jhep.2000.9635", "ArticleIdList": ["10.1053/jhep.2000.9635", "10960455"]}, {"Citation": "Grabowska AM, Lechner F, Klenerman P, Tighe PJ, Robins RA. Direct ex vivo comparison of the breadth and specificity of the Tcells in the liver and peripheral blood of patients with chronic HCV infection. Eur J Immunol. (2001) 31:2388\u201394. 10.1002/1521-4141(200108)31:8<2388::AID-IMMU2388>3.0.CO;2-L", "ArticleIdList": ["10.1002/1521-4141(200108)31:8<2388::AID-IMMU2388>3.0.CO;2-L", "11500822"]}, {"Citation": "Barnes E, Salio M, Cerundolo V, Francesco L, Pardoll D, Klenerman P, et al. . Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus. J Viral Hepat. (2010) 15:219\u201328. 10.1111/j.1365-2893.2007.00934.x", "ArticleIdList": ["10.1111/j.1365-2893.2007.00934.x", "PMC2268954", "18194173"]}, {"Citation": "Yang R, Gao N, Chang Q, Meng X, Wang W. The role of IDO, IL-10, and TGF-\u03b2 in the HCV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. J Med Virol. (2018) 91:265\u201371. 10.1002/jmv.25083", "ArticleIdList": ["10.1002/jmv.25083", "29611873"]}, {"Citation": "Chen YB, Li SD, He YP, Shi XJ, Chen Y, Gong JP. Immunosuppressive effect of IDO on T cells in patients with chronic hepatitis B. Hepatol Res. (2009) 39:463\u20138. 10.1111/j.1872-034X.2008.00476.x", "ArticleIdList": ["10.1111/j.1872-034X.2008.00476.x", "19207575"]}, {"Citation": "Ito H, Ando T, Ando K, Ishikawa T, Saito K, Moriwaki H, et al. . Induction of hepatitis B virus surface antigen-specific cytotoxic T lymphocytes can be up-regulated by the inhibition of indoleamine 2, 3-dioxygenase activity. Immunology. (2014) 142:614\u201323. 10.1111/imm.12274", "ArticleIdList": ["10.1111/imm.12274", "PMC4107671", "24580128"]}, {"Citation": "Schulz S, Landi A, Garg R, Wilson JA, van Drunen Littel-van den Hurk S. Indolamine 2,3-dioxygenase expression by monocytes and dendritic cell populations in hepatitis C patients. Clin Exp Immunol. (2015) 180:484\u201398. 10.1111/cei.12586", "ArticleIdList": ["10.1111/cei.12586", "PMC4449777", "25605587"]}, {"Citation": "Vega MD, Apar\u00edcio J, Retegui LA. Levo-1-methyl tryptophan aggravates the effects of mouse hepatitis virus (MHV-A59) infection. Int Immunopharmacol. (2015) 24:377\u201382. 10.1016/j.intimp.2014.12.031", "ArticleIdList": ["10.1016/j.intimp.2014.12.031", "25573404"]}, {"Citation": "Mdv A, Jla A, Mfmb C, Lar A. The autoimmune response elicited by mouse hepatitis virus (MHV-A59) infection is modulated by liver tryptophan-2,3-dioxygenase (TDO). Immunol Lett. (2020) 217:25\u201330. 10.1016/j.imlet.2019.11.004", "ArticleIdList": ["10.1016/j.imlet.2019.11.004", "31726186"]}, {"Citation": "Moffett JR, Ma AN. Tryptophan and the immune response. Immunol Cell Biol. (2003) 81:247\u201365. 10.1046/j.1440-1711.2003.t01-1-01177.x", "ArticleIdList": ["10.1046/j.1440-1711.2003.t01-1-01177.x", "12848846"]}, {"Citation": "Badawy AAB. Liver tryptophan 2,3-dioxygenase in the mouse hepatitis virus (MHV-A59) model. Immunol Lett. (2020) 225:23\u20134. 10.1016/j.imlet.2020.05.007", "ArticleIdList": ["10.1016/j.imlet.2020.05.007", "32540487"]}, {"Citation": "Sullivan DH, Roberson PK, Johnson LE. Association between inflammation-as-sociated cytokines, serum albumins, and mortality in the elderly. J Am Med Dir Assoc. (2007) 8:458\u201363. 10.1016/j.jamda.2007.04.004", "ArticleIdList": ["10.1016/j.jamda.2007.04.004", "17845949"]}, {"Citation": "Ingelsten M, Gustafsson K, Oltean M, Karlsson-Parra A, Olausson M, Haraldsson B, et al. . Is indoleamine 2,3-dioxygenase important for graft acceptance in highly sensitized patients after combined auxiliary liver-kidney transplantation? Transplantation. (2009) 88:911\u20139. 10.1097/TP.0b013e3181b72e49", "ArticleIdList": ["10.1097/TP.0b013e3181b72e49", "19935463"]}, {"Citation": "Sun X, Gong Z-J, Wang Z-W, Li T, Zhang J-Y, Sun H-C, et al. . IDO-competent-DCs induced by IFN-\u03b3 attenuate acute rejection in rat liver transplantation. J Clin Immunol. (2012) 32:837\u201347. 10.1007/s10875-012-9681-4", "ArticleIdList": ["10.1007/s10875-012-9681-4", "22454246"]}, {"Citation": "Weng MZ, Xu YG, Zhang Y, Zhang JY, Quan ZW, Xu JM, et al. . Indoleamine 2,3-dioxygenase as a predictor of acute rejection after orthotopic liver transplantation in rat model. Transplant Proc. (2011) 43:3969\u201372. 10.1016/j.transproceed.2011.09.061", "ArticleIdList": ["10.1016/j.transproceed.2011.09.061", "22172881"]}, {"Citation": "Lin YC, Goto S, Tateno C, Nakano T, Cheng YF, Jawan B, et al. . Induction of indoleamine 2,3-dioxygenase in livers following hepatectomy prolongs survival of allogeneic hepatocytes after transplantation. Transplant Proc. (2008) 40:2706\u20138. 10.1016/j.transproceed.2008.08.001", "ArticleIdList": ["10.1016/j.transproceed.2008.08.001", "18929841"]}, {"Citation": "Hepatol J. Liver regeneration. J Hepatol. (2012) 57(Suppl. 1):692\u20134. 10.1016/j.jhep.2012.04.016", "ArticleIdList": ["10.1016/j.jhep.2012.04.016", "22613006"]}, {"Citation": "Tacke F, Luedde T, Trautwein C. Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol. (2009) 36:4\u201312. 10.1007/s12016-008-8091-0", "ArticleIdList": ["10.1007/s12016-008-8091-0", "18600481"]}, {"Citation": "Ogiso H, Ito H, Kanbe A, Ando T, Hara A, Shimizu M, et al. . The inhibition of indoleamine 2,3-dioxygenase accelerates early liver regeneration in mice after partial hepatectomy. Dig Dis Sci. (2017) 62:2386\u201396. 10.1007/s10620-017-4651-6", "ArticleIdList": ["10.1007/s10620-017-4651-6", "28639129"]}, {"Citation": "Miki T, Sun H, Lee YH, Tandin A, Valdivia LA. Blockade of tryptophan catabolism prevents spontaneous tolerogenicity of liver allografts. Transplant Proc. (2001) 33:129\u201330. 10.1016/S0041-1345(00)02792-5", "ArticleIdList": ["10.1016/S0041-1345(00)02792-5", "11266740"]}, {"Citation": "Laurence JM, Wang C, Park ET, Buchanan A, Clouston A, Allen R, et al. . Blocking indoleamine dioxygenase activity early after rat liver transplantation prevents long-term survival but does not cause acute rejection. Transplantation. (2008) 85:1357\u201361. 10.1097/TP.0b013e31816fc27f", "ArticleIdList": ["10.1097/TP.0b013e31816fc27f", "18475196"]}, {"Citation": "Laurence JM, Wang C, Zheng M, Cunningham S, Earl J, Tay SS, et al. . Overexpression of indoleamine dioxygenase in rat liver allografts using a high-efficiency adeno-associated virus vector does not prevent acute rejection. Liver Transpl. (2009) 15:233\u201341. 10.1002/lt.21662", "ArticleIdList": ["10.1002/lt.21662", "19177450"]}, {"Citation": "Pree I, Bigenzahn S, Fuchs D, Koporc Z, Nierlich P, Winkler C, et al. . CTLA4Ig promotes the induction of hematopoietic chimerism and tolerance independently of indoleamine-2,3-dioxygenase. Transplantation. (2007) 83:663\u20137. 10.1097/01.tp.0000255594.23445.29", "ArticleIdList": ["10.1097/01.tp.0000255594.23445.29", "PMC2992942", "17353791"]}, {"Citation": "Wu Y, Wang Y, Li M, Yang X, Gong J, Zhang W. Gadolinium chloride suppresses acute rejection and induces tolerance following rat liver transplantation by inhibiting kupffer-cell activation. Exp Ther Med. (2014) 8:1777\u201382. 10.3892/etm.2014.2015", "ArticleIdList": ["10.3892/etm.2014.2015", "PMC4217766", "25371732"]}, {"Citation": "Anthonyj D, Kennethp B, Amarp D, Lindaferrell J, Stephena G, Johnhart P, et al. . Banff schema for grading liver allograft rejection: An international consensus document. Hepatology. (1997) 25:658\u201363. 10.1002/hep.510250328", "ArticleIdList": ["10.1002/hep.510250328", "9049215"]}, {"Citation": "Mulley WR, Nikolic-Paterson DJ. Indoleamine 2,3-dioxygenase in transplantation. Nephrology. (2010) 13:204\u201311. 10.1111/j.1440-1797.2007.00921.x", "ArticleIdList": ["10.1111/j.1440-1797.2007.00921.x", "18221253"]}, {"Citation": "Yakun Wu ZY, Junhua G, Min L, Yiming L, Jianping G. Effects of combined genes of CTLA4Ig and IDO in post-liver transplantation immune tolerance of rats. Ann Hepatol. (2016) 15:729-37. 10.5604/16652681.1212524", "ArticleIdList": ["10.5604/16652681.1212524", "27493112"]}, {"Citation": "Keenan BP, Fong L, Kelley RK. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J Immunother Cancer. (2019) 7:267. 10.1186/s40425-019-0749-z", "ArticleIdList": ["10.1186/s40425-019-0749-z", "PMC6798343", "31627733"]}, {"Citation": "Wang Y, Yao R, Zhang L, Xie X, Chen R, Ren Z. IDO and intra-tumoral neutrophils were independent prognostic factors for overall survival for hepatocellular carcinoma. J Clin Lab Anal. (2019) 33:e22872. 10.1002/jcla.22872", "ArticleIdList": ["10.1002/jcla.22872", "PMC6595287", "30843276"]}, {"Citation": "Davar D, Bahary N. Modulating tumor immunology by inhibiting indoleamine 2,3-dioxygenase (IDO): recent developments and first clinical experiences. Target Oncol. (2018) 13:125\u201340. 10.1007/s11523-017-0547-9", "ArticleIdList": ["10.1007/s11523-017-0547-9", "29302770"]}, {"Citation": "Ala M. The footprint of kynurenine pathway in every cancer: a new target for chemotherapy. Eur J Pharmacol. (2021) 896:173921. 10.1016/j.ejphar.2021.173921", "ArticleIdList": ["10.1016/j.ejphar.2021.173921", "33529725"]}, {"Citation": "Prendergast GC, Mondal A, Dey S, Laury-Kleintop LD, Muller AJ. Inflammatory reprogramming with IDO1 inhibitors: turning immunologically unresponsive 'cold' tumors 'hot'. Trends Cancer. (2018) 4:38\u201358. 10.1016/j.trecan.2017.11.005", "ArticleIdList": ["10.1016/j.trecan.2017.11.005", "PMC6015766", "29413421"]}, {"Citation": "Lilla H, Nikoletta D, G\u00e1bor K, Zsolt K, D\u00e9nes P, Zolt\u00e1n S, et al. . The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy. Front Immunol. (2018) 9:151. 10.3389/fimmu.2018.00151", "ArticleIdList": ["10.3389/fimmu.2018.00151", "PMC5797779", "29445380"]}, {"Citation": "Francesca F, Ursula G, Sylvaine Y, Barbara CM, Douglas RC, Carmine V, et al. . The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor \u03b6-chain and induce a regulatory phenotype in naive T cells. J Immunol. (2006) 176:6752\u201361. 10.4049/jimmunol.176.11.6752", "ArticleIdList": ["10.4049/jimmunol.176.11.6752", "16709834"]}, {"Citation": "Munn DH, Sharma MD, Johnson TS, Rodriguez P. IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment. Cancer Immunol Immunother. (2017) 66:1\u201310. 10.1007/s00262-017-2010-2", "ArticleIdList": ["10.1007/s00262-017-2010-2", "PMC5627605", "28488123"]}, {"Citation": "Holmgaard RB, Zamarin D, Li Y, Gasmi B, Wolchok JD. Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Rep. (2015) 13:412\u201324. 10.1016/j.celrep.2015.08.077", "ArticleIdList": ["10.1016/j.celrep.2015.08.077", "PMC5013825", "26411680"]}, {"Citation": "Ornstein MC, Diaz-Montero CM, Rayman P, Elson P, Haywood S, Finke JH, et al. . Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. Urol Oncol. (2018) 36:405\u201312. 10.1016/j.urolonc.2018.02.018", "ArticleIdList": ["10.1016/j.urolonc.2018.02.018", "29606341"]}, {"Citation": "Pan K, Wang H, Chen M-S, Zhang H-K, Weng D-S, Zhou J, et al. . Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol. (2008) 134:1247\u201353. 10.1007/s00432-008-0395-1", "ArticleIdList": ["10.1007/s00432-008-0395-1", "18438685"]}, {"Citation": "Han Y, Chen Z, Yang Y, Jiang Z, Gu Y, Liu Y, et al. . Human CD14+CTLA-4+regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. Hepatology. (2014) 59:567\u201379. 10.1002/hep.26694", "ArticleIdList": ["10.1002/hep.26694", "23960017"]}, {"Citation": "Tuanjie Li YY, Xuefeng H, Guoying W, Wei L, Changchang J, Yan T, et al. . Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 IDO. Cancer Let. (2012) 318:154\u201361. 10.1016/j.canlet.2011.12.020", "ArticleIdList": ["10.1016/j.canlet.2011.12.020", "22182446"]}, {"Citation": "Ishio T, Goto S, Tahara K, Tone S, Kitano S. Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J Gastroenterol Hepatol. (2010) 19:319\u201326. 10.1111/j.1440-1746.2003.03259.x", "ArticleIdList": ["10.1111/j.1440-1746.2003.03259.x", "14748880"]}, {"Citation": "Hiroaki I, Lloyd JO, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. (2002) 13:95\u2013109. 10.1016/S1359-6101(01)00038-7", "ArticleIdList": ["10.1016/S1359-6101(01)00038-7", "11900986"]}, {"Citation": "Lee IC, Huang YH, Chau GY, Huo TI, Su CW, Wu JC, et al. . Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments. Int J Cancer. (2013) 133:2895\u2013902. 10.1002/ijc.28311", "ArticleIdList": ["10.1002/ijc.28311", "23749461"]}, {"Citation": "Attallah AM, El-Far M, Zahran F, Shiha GE, Farid K, Omran MM, et al. . Interferon-gamma is associated with hepatic dysfunction in fibrosis, cirrhosis, and hepatocellular carcinoma. J Immunoassay Immunochem. (2016) 37:597\u2013610. 10.1080/15321819.2016.1179646", "ArticleIdList": ["10.1080/15321819.2016.1179646", "27093468"]}, {"Citation": "Brown ZJ, Yu SJ, Heinrich B, Ma C, Fu Q, Sandhu M, et al. . Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma. Cancer Immunol Immunother. (2018) 67:1305\u201315. 10.1007/s00262-018-2190-4", "ArticleIdList": ["10.1007/s00262-018-2190-4", "PMC6085109", "29959458"]}, {"Citation": "Long GV, Dummer R, Hamid O, Gajewski TF, Mitchell TC. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. (2019) 20:1083\u201397. 10.1016/S1470-2045(19)30274-8", "ArticleIdList": ["10.1016/S1470-2045(19)30274-8", "31221619"]}, {"Citation": "Ming L, Wang X, Wang L, Ma X, Gong Z, Zhang S, et al. . Targeting the IDO1 pathway in cancer: from bench to bedside. J Hematol Oncol. (2018) 11:100. 10.1186/s13045-018-0644-y", "ArticleIdList": ["10.1186/s13045-018-0644-y", "PMC6090955", "30068361"]}, {"Citation": "Muller AJ, Manfredi MG, Zakharia Y, Prendergast GC. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. Semin Immunopathol. (2018) 41:41\u20138. 10.1007/s00281-018-0702-0", "ArticleIdList": ["10.1007/s00281-018-0702-0", "30203227"]}, {"Citation": "G\u00fcnther J, Dbritz J, Wirthgen E. Limitations and off-target effects of tryptophan-related IDO inhibitors in cancer treatment. Front Immunol. (2019) 10:1801. 10.3389/fimmu.2019.01801", "ArticleIdList": ["10.3389/fimmu.2019.01801", "PMC6682646", "31417567"]}, {"Citation": "van Doorn DJ, Takkenberg RB, Kl\u00fcmpen H-J. Immune checkpoint inhibitors in hepatocellular carcinoma: an overview. Pharmaceuticals. (2020) 14:3. 10.3390/ph14010003", "ArticleIdList": ["10.3390/ph14010003", "PMC7821931", "33374927"]}, {"Citation": "Ferdinande L, Decaestecker C, Verset L, Mathieu A, Lopez XM, Negulescu AM, et al. . Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer. Br J Cancer. (2012) 106:141\u20137. 10.1038/bjc.2011.513", "ArticleIdList": ["10.1038/bjc.2011.513", "PMC3251860", "22108515"]}, {"Citation": "Riesenberg R, Weiler C, Spring O, Eder M, Buchner A, Popp T, et al. . Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res. (2007) 13:6993\u20137002. 10.1158/1078-0432.CCR-07-0942", "ArticleIdList": ["10.1158/1078-0432.CCR-07-0942", "18056175"]}, {"Citation": "Ludovini V, Bianconi F, Siggillino A, Vannucci J, Baglivo S, Berti V, et al. . High PD-L1/IDO-2 and PD-L2/IDO-1 co-expression levels are associated with worse overall survival in resected non-small cell lung cancer patients. Genes. (2021) 12:273. 10.3390/genes12020273", "ArticleIdList": ["10.3390/genes12020273", "PMC7918978", "33671892"]}, {"Citation": "Melaiu O, Lucarini V, Giovannoni R, Fruci D, Gemignani F. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. Semin Cancer Biol. (2020) S1044-579X:30156\u20135. 10.1016/j.semcancer.2020.07.001", "ArticleIdList": ["10.1016/j.semcancer.2020.07.001", "32659257"]}, {"Citation": "Lee JB, Ha SJ, Kim HR. Clinical insights into novel immune checkpoint inhibitors. Front Pharmacol. (2021) 12:681320. 10.3389/fphar.2021.681320", "ArticleIdList": ["10.3389/fphar.2021.681320", "PMC8139127", "34025438"]}, {"Citation": "Wang Z, Zhu J, Liu Y, Liu C, Ma L. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma. J Transl Med. (2020) 18:67. 10.1186/s12967-020-02255-6", "ArticleIdList": ["10.1186/s12967-020-02255-6", "PMC7011553", "32046766"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "9", "Day": "10"}, {"Year": "2021", "Month": "10", "Day": "22"}, {"Year": "2021", "Month": "12", "Day": "6", "Hour": "9", "Minute": "21"}, {"Year": "2021", "Month": "12", "Day": "7", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "12", "Day": "7", "Hour": "6", "Minute": "1"}, {"Year": "2021", "Month": "11", "Day": "18"}], "PublicationStatus": "epublish", "ArticleIdList": ["34869457", "PMC8636938", "10.3389/fmed.2021.756435"]}}], "PubmedBookArticle": []}